PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for pancreatic cancer: targeted drug trial launches
Disease control Not yet recruitingThis study tests a drug called sacituzumab tirumotecan in 30 people with advanced pancreatic cancer that has worsened after at least one prior treatment. The drug is given by IV every two weeks and aims to shrink tumors by targeting a protein called TROP-2. Researchers will measu…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 23, 2026 22:05 UTC
-
Targeted chemo delivery aims to boost pancreatic cancer surgery success
Disease control Not yet recruitingThis early-phase trial tests whether delivering the chemotherapy drug gemcitabine directly into the artery feeding the tumor can improve surgical outcomes for people with borderline resectable pancreatic cancer. Ten participants will receive standard chemo and radiation, followed…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: University of Vermont • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
New drug aimed at slowing pancreatic cancer shows promise in early trial
Disease control Not yet recruitingThis study tests a new drug called HLX43 in 100 adults with advanced pancreatic cancer that has not responded to other treatments. The drug is designed to target and attack cancer cells while limiting harm to healthy cells. The goal is to see if it can shrink tumors or slow the d…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New drug targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis early-stage study tests a new drug, BPI-572270, in adults with advanced solid tumors (lung, colorectal, pancreatic) that have specific RAS gene mutations. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 120 participants who …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
New drug cocktail aims to shrink Hard-to-Treat gut cancers
Disease control Not yet recruitingThis study tests a new drug called SSGJ-706 combined with standard treatments for people with advanced cancers of the digestive system, including stomach, colon, pancreas, and esophagus. The goal is to see if the combination is safe and can shrink tumors. About 300 adults aged 18…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Not yet recruitingThis early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC
-
New blood test could spot deadly pancreatic cancer earlier
Diagnosis Not yet recruitingThis study will check how well a new blood test called Panuri can detect pancreatic cancer in people who have symptoms that might be caused by this disease. About 1,100 adults with symptoms like jaundice, weight loss, or stomach pain will take part. The goal is to see if the test…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: Urteste S.A • Aim: Diagnosis
Last updated Jun 18, 2026 11:51 UTC
-
Gut bugs and blood clues may guide pancreatic cancer therapy
Knowledge-focused Not yet recruitingThis study aims to find biological markers in the blood, immune system, and gut microbiome that can help doctors choose the best treatment for people with advanced pancreatic cancer that cannot be removed by surgery. Researchers will collect blood and stool samples from 140 parti…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:05 UTC
-
Simple squeeze test may reveal hidden clues in pancreatic cancer
Knowledge-focused Not yet recruitingThis study looks at whether measuring hand grip strength in adults with pancreatic cancer can give doctors useful information about how the disease and treatment are affecting the body. About 50 participants will squeeze a handheld device during regular clinic visits and fill out…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:03 UTC
-
Bile drain before pancreatic surgery: help or hindrance?
Knowledge-focused Not yet recruitingThis study looks at whether draining a blocked bile duct before surgery for pancreatic cancer changes the tumor's behavior or patient survival. Researchers will review medical records of 90 patients who had their pancreatic tumor removed over 8 years. They will compare those who …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: East Lancashire Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Jun 11, 2026 12:12 UTC
-
New blood test may spot hidden pancreatic cancer earlier after surgery
Knowledge-focused Not yet recruitingThis study looks at whether a new blood test can find tiny bits of tumor DNA left behind after pancreatic cancer surgery. About 30 adults who had their cancer removed will give blood samples at three key times over six months. The goal is to see if this test can detect remaining …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:10 UTC